Summary & Overview
HCPCS J3373: Vancomycin Hydrochloride Injection, 10 mg
HCPCS Level II code J3373 denotes a 10 mg injection of vancomycin hydrochloride, a parenteral antibiotic used for serious gram-positive infections. Nationally, this code is important for hospital and outpatient infusion billing, antimicrobial stewardship tracking, and payer-specific coverage determinations for parenteral therapies. It affects facility and professional claims where vancomycin is administered by clinicians.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is used across typical sites of service, common billing modifiers and claim considerations (listed separately), and contextual clinical use of vancomycin in acute care settings. The publication also provides benchmarking context and policy updates relevant to reimbursement and coding practice where available.
This summary equips billing managers, revenue cycle staff, and clinicians with a concise reference on the clinical and billing role of J3373, expected service settings, and the payer landscape that commonly covers parenteral vancomycin.
Billing Code Overview
HCPCS Level II code J3373 describes an injection of vancomycin hydrochloride, 10 mg. This code represents a parenteral antimicrobial medication administered for systemic bacterial infections where vancomycin is indicated.
-
Service type: Medication administration (intravenous or intramuscular injection) for antimicrobial therapy
-
Typical site of service: Hospital inpatient, hospital outpatient infusion centers, emergency department, and other acute care settings where parenteral antibiotics are given
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J3373 is an adult inpatient or outpatient who requires intravenous vancomycin for treatment of serious Gram-positive bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, complicated skin and soft tissue infections, or surgical-site infections. A common scenario: a 62-year-old hospitalized patient with fever, positive blood cultures for MRSA, and clinical signs of sepsis is initiated on weight‑based intravenous vancomycin. Pharmacy prepares vancomycin in 10 mg increments per the hospital’s compounding protocol; dosing is calculated (e.g., 15 mg/kg) and administered via IV infusion with therapeutic drug monitoring (trough or AUC-guided levels). Typical clinical workflow: order entry in the electronic medical record, pharmacist compounding and verification, nursing administration with infusion rate monitoring and documentation, and laboratory monitoring of serum vancomycin concentration and renal function. Typical sites of service include the inpatient hospital floor, intensive care unit, emergency department, and hospital-based outpatient infusion center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | Use when a portion of a single-use vial of vancomycin is discarded after preparation and the unused amount must be reported for inventory/oversight |